Terguride but not bromocriptine alleviated glucose tolerance abnormalities and hyperlipidaemia in obese and lean genetically hypertensive Koletsky rats
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
7711008
Knihovny.cz E-resources
- MeSH
- Bromocriptine pharmacology MeSH
- Hyperlipidemias blood MeSH
- Hypertension blood MeSH
- Insulin blood MeSH
- Blood Pressure drug effects MeSH
- Rats MeSH
- Lipids blood MeSH
- Lisuride analogs & derivatives pharmacology MeSH
- Disease Models, Animal MeSH
- Obesity blood MeSH
- Glucose Intolerance blood MeSH
- Rats, Inbred SHR MeSH
- Rats, Sprague-Dawley MeSH
- Rats, Wistar MeSH
- Sex Factors MeSH
- Body Weight drug effects MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Bromocriptine MeSH
- dironyl MeSH Browser
- Insulin MeSH
- Lipids MeSH
- Lisuride MeSH
Glucose tolerance, total plasma cholesterol and plasma triglycerides were studied in the genetically hypertensive obese Koletsky rats (SHR/N-cp) and in their lean siblings. The initial part of the glucose tolerance curve was substantially elevated in both obese and lean Koletsky animals compared to normotensive Wistar rats. The abnormal glucose tolerance in hypertensive rats was accompanied by increased total plasma cholesterol and plasma triglycerides. Long-term treatment with dopaminergic agonists terguride or bromocriptine (0.2 and 2.0 mg/kg/day, respectively) exerted similar effects on lipid metabolism but both drugs differed in their influence on glucose tolerance. Terguride lowered plasma lipids and normalized glucose tolerance in both obese and lean Koletsky rats. Bromocriptine reduced hyperlipidaemia but did not attenuate the abnormalities of glucose tolerance in either lean or obese Koletsky animals.